股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01696 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | ILS | | 0.01 ILS | | 10,000,000 | | 增加 / 減少 (-) | | | 0 | | | ILS | | 0 | | 本月底結存 | | | 1,000,000,000 | ILS | | 0.01 ILS | | 10,000,000 | 本月底法定/註冊股本總額： ILS 10,000,000 FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 致：香港交易及結算 ...

Core Viewpoint - The company has shown strong growth in new orders for its energy source equipment, particularly in the Asia-Pacific region, leading to double-digit year-on-year revenue growth in the third quarter of 2025 [1][2]. Group 1: Energy Source Equipment - The demand for energy source equipment in the Asia-Pacific market is robust, with new orders in Q3 showing double-digit growth [1]. - The company's energy source equipment revenue faced challenges in the first half of the year due to high interest rates and weak consumer demand in North America, but there has been a noticeable recovery in Q3 [2]. - The flagship energy source device, Alma Harmony, has received a strong market response since its global launch in March 2025, contributing to increased order volumes [2]. Group 2: Injection Fillers - The injection filler business experienced a significant growth of 218% in the first half of the year, demonstrating strong product capability and effective channel management [3]. - The company plans to enhance the promotion of Profhilo in Thailand and expand the sales of Revanesse in the UK, German-speaking regions, Australia, and New Zealand [3]. - The long-acting botulinum toxin product, DaxibotulinumtoxinA (达希斐), is set to be launched in China following approval in September 2024, which is expected to inject new growth momentum into the injection filler business [3][4]. Group 3: Market Potential - The penetration rate of botulinum toxin in China is currently below the global average, indicating significant growth potential as consumer awareness increases [3]. - The market structure differences between China and other countries highlight the potential for increased usage of botulinum toxin in the Chinese market, which is currently underdeveloped compared to hyaluronic acid [3]. - The company’s DaxibotulinumtoxinA product has shown rapid revenue growth since its approval in the U.S., with a 32% increase in revenue for the first three quarters of 2024, primarily driven by repeat purchases [4]. Group 4: Financial Projections - The company expects revenue to reach $382 million, $442 million, and $510 million for the years 2025, 2026, and 2027, respectively, with net profits projected at $29 million, $36 million, and $45 million [4]. - The earnings per share (EPS) are forecasted to be $0.06, $0.08, and $0.10 for the same years, indicating a favorable growth trajectory [4].

Investment Rating - The report assigns a rating of "Buy" to the company [4]. Core Insights - The company has demonstrated strong growth in new orders for Q3 2025, primarily driven by performance in the Chinese, Korean, and Thai markets. The flagship multi-functional device, Alma Harmony, has shown robust growth, contributing to a double-digit year-on-year increase in unaudited revenue for the quarter [1][2]. - The injection filling business has seen a remarkable growth of 218% in the first half of 2025, showcasing strong product capability and channel layout. The long-acting botulinum toxin, DaxibotulinumtoxinA (DAXXIFY), is progressing smoothly towards its expected launch in China [3][19]. - The penetration rate of botulinum toxin in the Chinese market remains below the global average, indicating significant growth potential. The company is well-positioned to capitalize on this opportunity with its DAXXIFY product, which has already seen rapid revenue growth in the U.S. market [4][29]. Summary by Sections Energy Source Equipment - The demand for energy source equipment in the Asia-Pacific market is strong, with new orders showing double-digit growth in Q3. The company’s energy source equipment business has rebounded significantly in Q3 2025 after facing challenges earlier in the year due to high interest rates and geopolitical tensions affecting North America [2][13]. - The flagship device, Alma Harmony, launched globally in March 2025, has received a strong market response, further boosting order volumes. The Soprano series laser devices have also performed well, particularly after the successful launch of "Titan Lift" in China [2][13]. Injection Filling - The injection filling business, particularly the hyaluronic acid products, has shown strong growth, with the company planning to enhance the promotion of Profhilo in Thailand and expand Revanesse sales in the UK, German-speaking regions, Australia, and New Zealand [3][19]. - The anticipated approval and launch of DAXXIFY in September 2024 is expected to inject new growth momentum into the injection filling business [3][19]. Botulinum Toxin - The Chinese botulinum toxin market is projected to grow steadily, with an expected market size of 14.3 billion yuan by 2025, reflecting a CAGR of 26% from 2019 to 2025. The current penetration rate of botulinum toxin in China is significantly lower than the global average, indicating ample room for growth [20][25]. - The company’s DAXXIFY product, which utilizes proprietary peptide exchange technology, is expected to achieve rapid market penetration in China due to its long-lasting effects and high safety profile [29][25]. Financial Forecast and Investment Recommendations - The company is projected to achieve revenues of $382 million, $442 million, and $510 million for 2025, 2026, and 2027, respectively, with corresponding net profits of $29 million, $36 million, and $45 million. The earnings per share (EPS) are expected to be $0.06, $0.08, and $0.10 for the same years [8][36]. - The report emphasizes that the energy source equipment business is expected to stabilize and recover, while the injection filling business is likely to see significant contributions from the upcoming DAXXIFY launch [8][35].

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: Sisram Medical Ltd 復銳醫療科技有限公司* 呈交日期: 2025年11月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01696 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | ILS | | 0.01 ILS | | 10,000,000 | | 增加 / 減少 (-) | | | 0 | | | ILS | | 0 | | 本月底結存 | | | 1,000,000,000 | ILS | | 0.01 ILS | | 10,000,000 | 本月 ...

Core Viewpoint - Foryou Medical Technology (01696) reported strong growth in new orders for Q3 2025, driven by performance in China, South Korea, and Thailand markets [1] Group 1: Financial Performance - The company achieved a double-digit year-on-year growth in unaudited revenue for the quarter [1] Group 2: Product Development and Market Expansion - The flagship multi-functional device, Alma Harmony, experienced steady growth during the quarter [1] - The company plans to enhance the penetration of the Soprano series in the Asia-Pacific region within the year [1] - There is a commitment to advance the commercial deployment of Universkin by Alma in the U.S. market [1] - The company is on track to orderly progress the commercialization of Daxif in mainland China [1]

Core Viewpoint - Foryou Medical Technology (01696) reported strong growth in new orders for Q3 2025, driven by performance in China, South Korea, and Thailand markets [1] Group 1: Financial Performance - The company achieved double-digit year-on-year growth in unaudited revenue for the quarter [1] Group 2: Product Development and Market Expansion - The flagship multi-functional device, Alma Harmony, experienced steady growth during the quarter [1] - The company plans to enhance the penetration of the Soprano series in the Asia-Pacific region within the year [1] - There is a commitment to advance the commercial deployment of Universkin by Alma in the U.S. market [1] - The company is on track to orderly progress the commercialization of Daxif in mainland China [1]

Core Viewpoint - Furuya Medical Technology (01696.HK) reported strong growth in new orders for Q3 2025, driven by performance in China, South Korea, and Thailand markets [1] Group 1: Financial Performance - The company achieved a double-digit year-on-year growth in unaudited revenue for the quarter [1] Group 2: Product Development and Market Expansion - The flagship multi-functional device, Alma Harmony, experienced steady growth during the quarter [1] - The company plans to enhance the penetration of the Soprano series in the Asia-Pacific region within the year [1] - There is a commitment to advance the commercial deployment of Universkin by Alma in the U.S. market [1] - The company is on track to orderly progress the commercialization of Daxif in mainland China [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 自願公告 業務更新 本公告由復銳醫療科技有限公司（「本公司」，連同其附屬公司統稱「本集團」）自願 發佈，以通知本公司股東及潛在投資者有關本集團的最新業務狀況。 本公司欣然宣布，本集團於二零二五年第三季度的新訂單保持強勁增長勢頭，主 要得益於中國、韓國及泰國市場的表現。旗下多功能旗艦設備Alma Harmony於 本季度實現穩健增長。因此，本集團本季度未經審核收益實現同比雙位數增長。 憑藉持續的市場開拓和需求挖掘，本集團將於年內進一步推動Soprano系列在亞 太地區的滲透，全力推進Universkin by Alma在美國市場的商業部署。同時，按計 劃有序推進達希斐在中國大陸的商業化進程。 Sisram Medical Ltd 復䢇醫療科技有限公司* （ 於 以 色 列 註 冊 成 立 的 有 限 公 司 ） （股份代號：1696） 本公告乃根據本公司董事會初步審閱本集團的未經審核營運數據初稿及董事會現 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 呈交日期: 2025年10月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01696 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | ILS | | 0.01 | ILS | | 10,000,000 | | 增加 / 減少 (-) | | | 0 | | | | ILS | | 0 | | 本月底結存 | | | 1,000,000,000 | ILS | | 0.01 | ILS | | 10,000,000 | 本月底法定/註冊股本總額： ILS 10,000,000 FF301 第 ...

Group 1 - Core viewpoint: Furuya Medical Technology (01696) saw a stock increase of over 6%, currently trading at 5.98 HKD with a transaction volume of 10.9752 million HKD [1] - Furuya Medical Technology announced a commercial distribution cooperation agreement with Fosun Wanbang, which will provide services for the product Botulinum Toxin Type A, branded as Daxife in mainland China [1] - The annual transaction cap for this agreement is set at 17 million USD for the period from yesterday until the end of this year and the next year [1] Group 2 - The product is intended for the temporary improvement of moderate to severe frown lines caused by the activity of the glabellar muscles in adults [1] - The agreement is expected to generate additional revenue for the company [1]